SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is an effective hypoglycemic agent in the management of type 2 diabetes (T2D), with significant improvements in glycemic control and favorable cardiovascular/renal benefits [1].